Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management

Min Jae Kang, MD1, Jung Sub Lim, MD, PhD2
1Department of Pediatrics, Seoul National University Hospital, Seoul, 2Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea

As chemotherapy and other sophisticated treatment strategies evolve and the number of survivors of long-term childhood cancer grows, the long-term complications of treatment and the cancer itself are becoming ever more important. One of the most important but often neglected complications is osteoporosis and increased risk of fracture during and after cancer treatment. Acquisition of optimal peak bone mass and strength during childhood and adolescence is critical to preventing osteoporosis later in life. However, most childhood cancer patients have multiple risk factors for bone mineral loss. Cancer itself, malnutrition, decreased physical activity during treatment, chemotherapeutic agents such as steroids, and radiotherapy cause bone mineral deficit. Furthermore, complications such as growth hormone deficiency and musculoskeletal deformity have negative effects on bone metabolism. Low bone mineral density is associated with fractures, skeletal deformity, pain, and substantial financial burden not only for childhood cancer survivors but also for public health care systems. Thus, it is important to monitor bone health in these patients and minimize their risk of developing osteoporosis and fragility fractures later in life.

Key words: Bone mineral density, Cancer, Fractures, Risk factors

Introduction

Overall long-term survival of childhood cancer patients is increasing and is estimated to be 74% to 80% because of early detection, evolution of chemotherapy, improved surgical techniques, refined radiation therapy, and hematopoietic stem cell transplantation (HSCT)1,2. It is estimated that 1 of every 640 young adults in the USA is a childhood cancer survivor (CCS)3. However, long-term survivors of childhood cancer (LTSCC) face increased risks of various health problems resulting from treatment or the cancer itself. These include secondary cancers, cardiac dysfunction, infertility, growth failure, endocrine deficiencies, renal damage, pulmonary toxicity, hearing loss, neuropsychiatric problems, obesity, and musculoskeletal abnormalities4,5. Among these, osteoporosis is of great importance because it can lead to fractures, pain, deformity, gait abnormality, and substantial financial burden6-8.

Osteoporosis was previously considered a disease of the elderly but is now considered to have a pediatric origin6. Individuals who fail to achieve optimal peak bone mass (PBM) and strength during childhood and adolescence are more likely to develop osteoporosis later in life9. LTSCC fail to achieve optimal PBM because of the cancer itself, malnutrition during chemotherapy, and decreased physical activity. The onset of most childhood cancers is in the second decade of life, when nearly 43% to 66% of maximal
adult bone mineral density (BMD) is gained\(^{10}\). Thus, LTSCC have a high prevalence of osteoporosis or low BMD, even in early adulthood\(^{11-22}\). Radiotherapy, chemotherapy, and hormone deficiencies are frequently cited as risk factors for osteoporosis and fractures in LTSCC\(^ {11,18,22}\).

In this review, we address the pathophysiology, prevalence, screening, and management of osteoporosis in CCSs. The objective is to raise awareness among pediatricians of the risk of osteoporosis in CCS and the 2008 Children’s Oncology Group (COG) long-term follow-up (LTFU) guidelines for bone mineral deficits\(^ {13}\).

Pathophysiology of BMD deficits in CCSs

The mechanism causing BMD deficits in CCS is multifactorial. It depends on cancer type, therapeutic modalities such as chemotherapeutic agents and radiation, and the occurrence of endocrine complications like growth hormone deficiency (GHD) and hypogonadism. In addition, other factors such as age at cancer diagnosis, sex, genetic predisposition, nutrition, and lifestyle affect BMD.

Cancer itself causes BMD deficits. Ten to twenty percent of children with acute lymphoblastic leukemia (ALL) exhibit reduced BMD at diagnosis\(^ {5,26}\). Leukemic infiltration of the bone and various factors secreted by leukemic cells, such as parathyroid hormone (PTH) and PTH-related peptide, were suggested as causes of BMD deficit\(^ {26}\). Some osteosarcoma patients have had BMD deficit in the affected limb, which initially presented with bone pain\(^ {26}\).

Chemotherapeutic agents such as corticosteroids, methotrexate, and alkylating agent are well known to cause BMD deficits directly or indirectly. Corticosteroids inhibit new bone formation by decreasing osteoblastic activity, including osteocalcin production, and by directly increasing osteoclastic bone resorption\(^ {29}\). Corticosteroids also inhibit 1α-hydroxylation of vitamin D and result in impaired intestinal absorption of calcium and reduced muscle strength. ALL patients administered a total corticosteroid dose greater than 9 g/m\(^2\) are more likely to develop reduced BMD that does not recover to within normal range after treatment\(^ {27}\). High-dose prednisone (≥20 g/m\(^2\)) is a risk factor for osteopenia in patients with malignant lymphoma\(^ {19}\).

Methotrexate also suppresses osteoblast activity and stimulates osteoclast recruitment, resulting in decreased bone formation and increased bone resorption\(^ {29}\). Higher cumulative doses of methotrexate have been associated with a greater incidence of osteopenia\(^ {29}\). Total doses of more than 4 g/m\(^2\) were associated with a high risk of osteopenia and failure to recover to a normal BMD after completion of therapy\(^ {16,27}\). Alkylating agents such as cyclophosphamide and ifosfamide cause hypogonadism and result in decreased BMD. Estrogens play a crucial role in achieving and maintaining PBM by preventing bone resorption and stimulating growth factors necessary for bone growth\(^ {29}\). Androgens seem to have an important role in periosteal apposition, adding to the biochemical strength of the bone\(^ {29}\). Ifosfamide also induces Fanconi syndrome, which can result in hypophosphatemia and severe metabolic bone disease. Other agents such as vincristine, daunorubicin, etoposide, and asparaginase reduce type I collagen synthesis\(^ {10}\). Vincristine also induces neuropathy, which leads to poor balance and increases the risk of falls.

Radiation is the most important risk factor for osteoporosis, especially in brain tumor survivors\(^ {46}\). Radiation might directly affect BMD by damaging the bone marrow stroma\(^ {11}\), but the principal cause is assumed to be deficiencies of hormones such as growth hormone (GH) and sex steroid\(^ {22,17}\). Cranial and total body irradiation (TBI) can lead to GHD and central hypogonadism, both of which are associated with BMD deficits\(^ {32}\). Children who received cranial irradiation at a dose of 24 Gy had reduced spontaneous and pulsatile GH secretion, while nonirradiated children had normal secretion\(^ {13}\). Fractionated TBI doses of >12 Gy for transplant conditioning may also result in GHD\(^ {13,18}\). Radiation-induced fractures in survivors treated with radiation doses of ≥40 Gy have been described\(^ {10}\).

Endocrine sequelae such as GHD and hypogonadism also cause BMD deficits in CCS. GH is important to acquiring adequate PBM and to maintaining bone mass\(^ {44}\). Not only radiation but also chemotherapy can cause GHD. Roman et al.\(^ {19}\) reported that 44% of a cohort of 25 children who had received chemotherapy and surgery for malignant solid tumors developed impaired GH secretion. GHD is related to low BMD in both adults and children\(^ {4,34,16}\). Baroncelli et al.\(^ {36}\) reported that lumbar BMD declined rapidly after discontinuation of GH in patients with GHD, compared with controls. We also reported that GH replacement was associated with increase in BMD in patients with intracranial germ cell tumors\(^ {46}\).

Hypogonadism is often caused by alkylating agents and radiation. Gonadotropin deficiency occurs with high-dose radiation (≥40 Gy) to the neuroendocrine axis\(^ {13}\). Peripheral hypogonadism occurs at much lower radiation doses. Ovarian dysfunction and premature menopause are associated with radiation doses of ≥10 Gy to the ovaries in prepubertal females and ≥5 Gy in pubertal females\(^ {32,16}\). In males, higher doses (≥20 Gy) are required to cause Leydig cell dysfunction with associated androgen insufficiency\(^ {7,18}\).

HSCT is well known to cause BMD deficits. Adult transplantation studies reported that a 2% to 10% loss of BMD significantly increased the risk of fractures\(^ {17}\). Childhood leukemia survivors with HSCT had gonadal deficiency and significantly lower femoral BMD as adults\(^ {49}\). Patients undergoing HSCT often...
receive multiple agents associated with altered bone metabolism, including methotrexate, steroids, TBI, and high-dose alkylating agents, as part of their treatment\textsuperscript{[19]}. In addition, altered kidney, liver, and bowel functions might result in reduced absorption and abnormal metabolism of calcium and vitamin D\textsuperscript{[20]}. Finally, the HSCT procedure itself has been reported to cause severe and persistent quantitative and qualitative impairment of osteoblastic precursors within the stromal stem cell compartment\textsuperscript{[20]}.

Some CCS may fail to achieve optimal PBM. To acquire adequate PBM, nutrition and physical activity are essential\textsuperscript{[19]}. However, most pediatric cancer patients do not regularly consume the recommended daily allowances of nutrients, including during cancer treatment. Such patients have been found to have altered metabolism of calcium, 1,25-dihydroxyvitamin D, and magnesium during prolonged periods of hospitalization and immobilization\textsuperscript{[20,40]}. During and after treatment, they were less involved in physical activities than healthy controls\textsuperscript{[22,42]}. Pain associated with osteopenia significantly limited physical activity in brain tumor survivors\textsuperscript{[12]}. Reduced exercise capacity was related to decreased bone mineralization in survivors of ALL\textsuperscript{[40]}. CCS seemed to have a higher prevalence of osteoporosis and fractures in males than in females\textsuperscript{[14,42-44]}. The longer period of pubertal development and partial hypogonadism in boys might contribute to this difference between sexes\textsuperscript{[14,43]}.

**Prevalence of BMD deficits in CCSs**

The exact prevalence of osteoporosis and osteopenia in CCS is difficult to show, although published studies have identified reduced BMD as a common finding in young adulthood. Most reports include small numbers of subjects, diverse malignant diseases, heterogeneity of therapeutic modalities, various age groups, different sites of BMD measurement, and different definitions of osteoporosis\textsuperscript{[19]}. The Children's Oncology Group Bone Health Committee suggested another criterion: Z-score less than -1.0 was defined as low BMD, and Z-score less than -2.5 as significantly low BMD. In our previous study, Z-scores of <-2.0 indicated osteoporosis, and Z-scores ≥-2.0 and <-1.0 indicated osteopenia in subjects younger than 20 years\textsuperscript{[14]}. For convenience, we used the terms “osteopenia” and “osteoporosis” when searching the literature. The prevalence rates of osteoporosis and osteopenia in CCS are summarized in Table 1.

1. **ALL**

At diagnosis, 10% to 20% of children with ALL exhibited reduced BMD at the lumbar spine\textsuperscript{[2,40]}. During therapy, additional bone mineral loss occurred, especially in early periods of intensified treatment, and approximately 50% of children had a reduction in BMD. Halton et al.\textsuperscript{[40]} reported that fractures occurred in 39% of children during treatment. Reports of results from after completion of therapy have been conflicting. Kaste et al.\textsuperscript{[41]} reported that ALL patients had a median BMD Z-score of -0.78 standard deviation (SD), and 21% had abnormally low BMD, compared to 5% in normal populations after 15.9 years. Hoorweg-Nijman et al.\textsuperscript{[19]} also concluded that bone development in patients cured of ALL is disturbed, resulting in a significantly reduced BMD. In a 24-year follow-up study, low BMD was found to be more prevalent (24%) than expected based on population normative data, specifically men\textsuperscript{[21]}. However, some reported normal BMD after cessation of ALL treatment\textsuperscript{[40-50]}. Brennan et al.\textsuperscript{[52]} reported that adult survivors of ALL whose treatment included cranial irradiation had reduced BMD, while those without cranial irradiation showed normal bone mineral apparent density (BMAD)\textsuperscript{[20]}.

2. **Lymphoma**

Osteopenia (Z-score<-1.00) was found in 41% (9/22) of patients with Hodgkin’s disease and 50% (10/20) of patients with non-Hodgkin’s lymphoma at the lumbar spine after 24.1 and 14.1 years of follow-up, respectively\textsuperscript{[19]}. The use of mechlorethamine, oncovin, procarbazine, and prednisone led to decreased height and increased body mass index in men and decreased total body BMD in women\textsuperscript{[54]}. High cumulative dose of corticosteroids, especially, was a risk factor for osteopenia\textsuperscript{[19]}.

3. **Brain tumors**

Osteoporosis is a common sequel of therapy in children with brain tumors. We previously reported that 25.0% of patients with germ cell tumors had osteoporosis and 42.9% had osteopenia at 10.9-year follow-up\textsuperscript{[14]}. The prevalence of osteoporosis (bone mineral contents Z-score<-2.5) in the entire body was more than 40% in the irradiated group and 0% in the nonirradiated group of patients with posterior fossa tumors or optic gliomas\textsuperscript{[46]}. Barr et al.\textsuperscript{[19]} also reported that BMD decreased at the lumbar
spine (mean Z-score, -1.05) and femoral neck (mean Z-score, -0.84), with an overall osteopenia prevalence of 47.3%, in brain tumor survivors. Previous reports have showed that survivors of various childhood brain tumors are susceptible to development of fractures and early osteoporosis, especially in association with the risk factor GHD\textsuperscript{17,45}.

4. Other solid tumors

Low BMD in has been reported in survivors of various other solid tumors\textsuperscript{23}. Osteopenia or osteoporosis was reported in 28.3% to 65% of survivors of osteogenic sarcoma or Ewing’s sarcoma\textsuperscript{16,55,56}. Holzer et al.\textsuperscript{16} reported that 65% of osteosarcoma patients had BMD deficits at the age of 31±4.2 years, and the mean duration of follow-up from diagnosis was 16±2.2 years. We also found that 47.5% of long-term survivors of osteosarcoma had osteoporosis and 30.0% had osteopenia at the age of 22.0±5.1 years (unpublished data). A high incidence of osteopenia (26%) was found in survivors of Wilms’ tumor\textsuperscript{55} and brain tumor survivors. Previous reports have showed that survivors of various childhood brain tumors are susceptible to development of fractures and early osteoporosis, especially in association with the risk factor GHD\textsuperscript{17,45}.

Table 1: Prevalence of osteopenia and osteoporosis in childhood cancer survivors

| Cancer type | No. | Mean age at cancer diagnosis (yr) | Mean age at BMD evaluation (yr) | DXA sites | Mean Z-score | % of low BMD | Risk factors for BMD deficit in the study | Reference |
|-------------|-----|----------------------------------|--------------------------------|------------|--------------|-------------|------------------------------------------|-----------|
| All cancers | 40  | 12.7                             | 25.6                           | LS 2-4 FN  | -0.22        | NA          | Gonadal dysfunction                       | Aisenberg et al.\textsuperscript{17} |
| Non-CNS cancers | 519 | 4.8                              | 12.1                           | NA         | NA           | 8.1         | NA                                       | Patterson et al.\textsuperscript{69} |
| ALL | 24  | 6.8                              | 25.1                           | LS 1-4 FN  | -1.07        | (low BMD, Z-score<-2.0) 45.8 | Impaired GH secretion                       | Hoorweg-Nijman et al.\textsuperscript{73} |
| ALL | 74  | 5.64                             | 30.04                          | LS 2-4 FN  | 0.13         | 24          | Ht Z-scores<-1.0 in female Male gender Cranial RTx>24 Gy Low IGF-1 level | Thomas et al.\textsuperscript{71} |
| ALL/NHL | 89  | 4.8                              | 24.7                           | LS 1-4 FN  | -0.60        | 49          | Prophylactic cranial RTx TBI-conditioned BMT Male gender at LS Previous dexamethasone treatment Low final Ht and bone size | Benmiloud et al.\textsuperscript{39} |
| HD NHL | 22  | 14.7                             | 24.1                           | LS         | -0.55        | 45.2        | High cumulative dose of corticosteroids   | Sala et al.\textsuperscript{18} |
| Intracranial GCT | 28  | 11.6                             | 23.1                           | LS 1-4 FN  | -1.1         | 67.9 (42.9/25.0) | Male gender Low lean mass Delayed start of adult GH replacement | Kang et al.\textsuperscript{14} |
| Brain tumor Astrocystoma, CRP, GCT, Ependymoma MBL, PBL | 36  | 8.4                              | 16.9                           | LS 1-4 FN  | -0.91        | (osteoporosis, Z-score<-2) 44 (19/25) 59 (42/17) 50 (28/22) | Fracture history Un-treated GHD | Cohen et al.\textsuperscript{17} |
| Osteosarcoma | 48  | 15                               | 31.0                           | LS 1-4 FN  | -0.49        | 64.5 (43.7/20.8) | Age at surgery In female, hypoestrogen status | Holzer et al.\textsuperscript{16} |
| Sarcoma Ewing+OSA | 46  | 13.9                             | 14.3                           | LS 2-4    | -0.14        | 28.3 (26.1/2.2) | Tumor location (lower extremity) with offloading recommendation | Muller et al.\textsuperscript{56} |
| Solid tumor Lymphoma Sarcoma WT, NBL | 38  | 8.9                              | 22.0                           | LS 2-4 UD+1/3D radius total hip+FN | NA | 34 (24/8) exclude forearm 50 include forearm | No. of chemotherapy drugs | Kelly et al.\textsuperscript{50} |
| NBL | 27  | 6.1                              | 6.1                            | LS2-4 Total body | 0.65         | (osteoporosis, Z-score<-2) 26 (11/15) | Advanced stage of NBL with diffuse Al-Tonbary et al.\textsuperscript{58} bone and bone marrow metastasis | |

BMD, bone mineral density; DXA, dual energy X-ray absorptiometry; LS, lumbar spine; FN, femur neck; 1/3 D radius, 1/3 distal radius; NA, not available; CNS, central nervous system; ALL, acute lymphoblastic leukemia; UD, ultradistal; GH, growth hormone; Ht, height; RTx, irradiation; IGF-1, insulin-like growth factor 1; NHL, non-Hodgkin’s lymphoma; TBI, total body irradiation; BMT, bone marrow transplantation; HD, Hodgkin’s disease; GCT, germ cell tumor; CRP, craniopharyngioma; MBL, medulloblastoma; PBL, pineoblastoma; FT, femur total; OSA, osteosarcoma; WT, Wilms’ tumor; NBL, neuroblastoma.
neuroblastoma. Low bone mass may occur in children at initial diagnosis of neuroblastoma and before the start of chemotherapy or radiotherapy, especially if the disease is at an advanced stage with diffuse bone and bone marrow metastases.

5. HSCT

HSCT recipients had reduced BMD at multiple skeletal sites and BMAD in the spine when compared with controls. In a prospective study, BMD of the spine and hip gradually decreased over 12 to 14 months after allogeneic HSCT. Kaste et al. reported that after a median follow-up of 5.1 years, allogeneic HSCT recipients had a median BMD Z-score of -0.89, and 14.6% had osteopenia. In a 14-year follow-up study, acute leukemia patients in the HSCT group had a significantly reduced femoral neck BMD (mean BMD Z-score, -0.49) compared with patients who did not receive a transplant, and 7.4% of them had a history of fracture. Children who were younger at the time of transplantation had a significantly higher risk of low spinal BMD during adulthood. Bone loss seemed to be worse after allogeneic HSCT than after autologous HSCT, probably because of a prolonged and greater cytokine release after transplantation and because use of immunosuppressive agents is more important after allogeneic transplantation.

Screening and management

The high prevalence of osteoporosis, even in early adulthood, in CCS suggests that specific diagnosis and treatment may be beneficial, although there is still no consensus on the treatment of osteoporosis in the young. The 2008 COG LTFU guidelines recommended a baseline evaluation of BMD by dual-energy X-ray absorptiometry or quantitative computed tomography at entry into LTFU for patients exposed to methotrexate, corticosteroids, and HSCT and who have medical conditions such as GHD, hypogonadism, delayed puberty, or hyperthyroidism. Some experts even insist that children with brain cancer should be evaluated for BMD immediately, because most cancer treatment protocols are risk factors for bone mineral deficit. BMD should be evaluated with robust normative data; fortunately, we have normative data for Korean children and adolescents.

The management algorithm for osteoporosis in CCS is shown in Fig. 1. All CCS should undergo prophylaxis for bone loss and fractures (Table 2). Repeat measurements are not required for patients with normal baseline BMD results (BMD Z-score > -1). The COG LTFU guidelines recommend 800 to 1,500 mg of calcium and 200 IU vitamin D daily intake, through diet or supplementation. However, pediatricians should be aware of the fact that most Korean children and adolescents are not receiving the recommended dietary intake of calcium and vitamin D. Recently, the U.S. Institute of Medicine issued a new clinical guideline on vitamin D. According to this guideline, 600 IU vitamin D is needed to maintain 25-hydroxyvitamin D at more than 20 ng/mL. Considering the fact that corticosteroids reduce intestinal calcium absorption and increase calcium excretion, adequate intake of calcium and vitamin D is an important prevention strategy. Up to 1,500 to 2,000 IU vitamin D is needed in cases of vitamin D deficiency.

If BMD Z-score is between -1.0 and -2.0, regular follow-up is required. Treatment of BMD deficits in children includes

![Fig. 1. Algorithm to prevent osteoporosis in childhood cancer survivors. LTFU, long-term follow-up; GHD, growth hormone deficiency; DXA, dual energy X-ray absorptiometry; BMD, bone mineral density.](http://dx.doi.org/10.3345/kjp.2013.56.2.60)
methotrexate, or HSCT is associated with an increased risk of BMD deficits. Radiation and alkylating chemotherapy increase the risk of endocrinopathies that predispose patients to reduced BMD. Genetic predisposition and lifestyle may also contribute to BMD deficits. Pediatricians should be aware that CCS are at risk for osteoporosis and require appropriate early intervention.

Conclusions

Survivors of childhood and adolescent cancers are at risk for osteoporosis (or low bone mass for chronologic age) during and after completion of therapy. Treatment with corticosteroids, methotrexate, or HSCT is associated with an increased risk of BMD deficits. Vitamin D supplementation: at least 200 IU (Institute of Medicine recommends 600 IU). Multivitamin tablet containing vitamin K.

References

1. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009;27:2308-18.
2. National Cancer Registration and Statistics System. Annual report of cancer statistics in Korea [Internet]. Goyang: Korea Central Cancer Registry; [c2012] [cited 2010 Dec 1]. Available from: http://nccr.cancer.go.kr/index.do.
3. Spechley KN, Barrera M, Shaw AK, Morrison HI, Maunsell E. Health-related quality of life among child and adolescent survivors of childhood cancer. J Clin Oncol 2006;24:2536-43.
4. Robison LL, Green DM, Hudson M, Meadows AT, Mertens AC, Packer RJ, et al. Long-term outcomes of adult survivors of childhood cancer. Cancer 2005;104(11 Suppl):2557-64.
5. Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine sequelae of cancer and cancer treatments. J Cancer Surviv 2007;1(2):261-74.
6. Cooper C, Westlake S, Harvey N, Javaid K, Dennison E, Hanson M. Review: developmental origins of osteoporotic fracture. Osteoporos Int 2006;17:337-47.
7. van der Sluis IM, van den Heuvel-Eibrink MM, Hahlen K, Krenning EP, de Muinck Keizer-Schrama SM. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 2002;141:204-10.
8. Rizzoli R, Bianchi ML, Garabedian M, McKay HA, Moreno LA. Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone 2010;46:294-305.
9. Mora S, Gilzanz V. Establishment of peak bone mass. Endocrinol Metab Clin North Am 2003;32:39-63.
10. Lim JS, Hwang JS, Lee JA, Kim DH, Park KD, Cheon GJ, et al. Bone mineral density according to age, bone age, and pubertal stages in Korean children and adolescents. J Clin Densitom 2010;13:68-76.
11. Aisenberg J, Hsieh K, Kalaitzoglou G, Whittam E, Heller G, Schneider R, et al. Bone mineral density in young adult survivors of childhood cancer. J Pediatr Hematol Oncol 1998;20:241-5.
12. Barr RD, Simpson T, Webber CE, Gill GJ, Hay J, Eves M, et al. Osteopenia in children surviving brain tumours. Eur J Cancer 1998;34:873-7.
13. Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, ver. 3.0 [Internet]. [Philadelphia]: Children’s Oncology Group; [c2012] [cited 2012 Oct 15]. Available from: http://www.survivorshipguidelines.org.
14. Kang MJ, Kim SM, Lee YA, Shin CH, Yang SW, Lim JS. Risk factors for osteoporosis in long-term survivors of intracranial germ cell tumors. Osteoporos Int 2012;23:1921-9.
15. Sala A, Talsma D, Webber C, Posgate S, Atkinson S, Barr R. Bone mineral status after treatment of malignant lymphoma in childhood and adolescence. Eur J Cancer (Engl) 2007;16:373-9.
16. Holzer G, Krepler P, Koschat MA, Grampp S, Dominikus M, Kotz R.

Table 2. Prevention of bone loss and fractures in childhood cancer survivors

| Prevention of bone loss and fractures in childhood cancer survivors |
|---------------------------------------------------------------|
| Perform BMD test at the beginning of treatment or off therapy. |
| Adequate calcium intake: 800 to 1,500 mg daily (for 10 to 50 years old). |
| Patients with diagnosed osteoporosis should receive 1,500 mg of calcium daily. |
| Vitamin D supplementation: at least 200 IU (Institute of Medicine recommends 600 IU). |
| Multivitamin tablet containing vitamin K. |
| Adequate sunlight exposure. |
| Weight-bearing and resistance-training exercises to prevent proximal muscles weakness. |
| When feasible, avoid or reduce steroids, antiepileptic drugs (phenobarbital, phenytion, carbamazepine, and primidone), LMWH and unfractioned heparin. |
| In case of severe BMD deficit (osteoporosis), consult pediatric endocrinologist. |

BMD, bone mineral density; LMWH, low molecular weight heparin.

increasing weight-bearing exercise as tolerated, optimizing nutritional intake of calcium and vitamin D, nutrient supplementation if dietary intake is insufficient, and treatment of conditions that may exacerbate BMD deficit, such as hypogonadism or GHD. Running or jumping has been proven to positively affect BMD. Supplementation with vitamin D and increased calcium intake have been proven to enhance PBM in healthy children. Counseling survivors about avoiding smoking, alcohol, and caffeine is also important, as all of these can exacerbate BMD deficits.

If BMD Z-score is less than -2.0, recurrent fractures, latent medical risk factors for decreased BMD, and hormonal risk factors such as hypogonadism or GHD should be considered. Endocrinology consultation may be advisable. Pediatric endocrinologists should thoroughly evaluate BMD and osteoporosis risk factors in cancer survivors. They also should consider treatment options such as bisphosphonates, although bisphosphonates are currently reserved for patients with recurrent fractures and clinical trial participants. Only a few publications on the use of bisphosphonates in pediatric cancer patients are available, but reports of bisphosphonate treatment benefit in cancer patients are limited.

Pamidronate caused rapid pain relief, gradual improvement of BMD, and improved motor function. These are promising results, but long-term controlled studies are needed to assess the risks and benefits of bisphosphonates in children with osteoporosis.

References
Bone mineral density in long-term survivors of highly malignant osteosarcoma. J Bone Joint Surg Br 2003;85:231-7.

17. Cohen LE, Gordon JH, Popovsly EV, Sainath NN, Feldman HA, Kieran MW, et al. Bone density in post-pubertal adolescent survivors of childhood brain tumors. Pediatr Blood Cancer 2012; 58:959-63.

18. Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999;33:2-8.

19. Benmiloud S, Steffens M, Beauloye V, de Wandelere A, Devogelaer JP, Brichard B, et al. Long-term effects on bone mineral density of different therapeutic schemes for acute lymphoblastic leukemia or non-Hodgkin lymphoma during childhood. Horm Res Paediatr 2010;74:241-50.

20. Hoorweg-Nijman JJ, Kardos G, Roos JC, van Dijk HJ, Netelenbos C, Popp-Snijders C, et al. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukaemia. Clin Endocrinol (Oxf) 1999;50:237-44.

21. Thomas IH, Donohue JE, Ness KK, Dengel DR, Baker KS, Gurney JG. Bone mineral density in young adult survivors of acute lymphoblastic leukemia. Cancer 2008;113:2428-56.

22. Kelly J, Damron T, Grant W, Anker C, Holdridge S, Shaw S, et al. Cross-sectional study of bone mineral density in adult survivors of solid pediatric cancers. J Pediatr Hematol Oncol 2005;27:244-53.

23. Riemenschneider J, Diek JJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000;18:1570-91.

24. Krishnamoorthy P, Freeman C, Bernstein ML, Lawrence S, Brod C. Osteopenia in children who have undergone posterior fossa or cranioptasis irradiation for brain tumors. Arch Pediatr Adolesc Med 2004;158:491-6.

25. Halton JM, Atkinson SA, Fraher L, Webber CE, Cockshott WP, Tam C, et al. Mineral homeostasis and bone mass at diagnosis in children with acute lymphoblastic leukaemia. J Pediatr 1995;126:557-64.

26. Arikoski P, Komulainen J, Riikonen P, Voutilainen R, Knip M, Kroger H. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study. J Clin Endocrinol Metab 1999;84:3174-81.

27. Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol 2004;22:1215-21.

28. Wheeler DL, Vander Griend RA, Wronski TJ, Miller GJ, Keith EE, Graves JE. The short- and long-term effects of methotrexate on the rat skeleton. Bone 1995;16:215-21.

29. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005;328:686-96.

30. Davies JH, Evans BA, Jones E, Evans WD, Jenney ME, Gregory JW. Osteopenia, excess adiposity and hyperleptinaemia during 2 years of treatment for childhood acute lymphoblastic leukaemia without cranial irradiation. Clin Endocrinol (Oxf) 2004;60:358-65.

31. Tillmann V, Darlington AS, Eiser C, Bishop NJ, Davies HA. Male sex and low physical activity are associated with reduced spine bone mineral density in survivors of childhood acute lymphoblastic leukaemia. J Bone Miner Res 2002;17:1073-80.

32. Kaste SC, Jones-Wallace D, Rosi SR, Boyett JM, Lustig RH, Rivera GK, et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001;15:278-34.

33. Muller HL, Schneider P, Bueh K, Etavard-Gorris N, Gebhardt U, Kolb R, et al. Volumetric bone mineral density in patients with childhood craniopharyngioma. Exp Clin Endocrinol Diabetes 2003;111:168-73.

34. Gurney JG, Kadan-Lottick NS, Packer R, Neglia JP, Sklar CA, Punoiko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2004;97:663-73.

35. Odame I, Duckworth J, Tahma D, Beumont I, Furlong L, Webber C, et al. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. Pediatr Blood Cancer 2006;46:357-62.

36. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008;43:1115-21.

37. Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996;11:1774-83.

38. van der Sluis IM, van den Heuvel-Eibrink MM, Hahnen K, Krens E, de Ruiter ME, Peeters MC, et al. Changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) 2003;60:175-84.

39. Mattano L. The skeletal remains: porosis and necrosis of bone in the marrow transplantation setting. Pediatr Transplant 2003;7 Suppl 3:71-5.

40. Le Meignen M, Auquier P, Barlogis V, Sirvent N, Contet A, Simeoni MC, et al. Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 2011;118:1481-9.

41. Muller HL, Schneider P, Bueh K, Etavard-Gorris N, Gebhardt U, Kolb R, et al. Volumetric bone mineral density in patients with childhood craniopharyngioma. Exp Clin Endocrinol Diabetes 2003;111:168-73.

42. Gurney JG, Kadan-Lottick NS, Packer R, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003;97:663-73.

43. Odame I, Duckworth J, Tahma D, Beumont I, Furlong L, Webber C, et al. Osteopenia, physical activity and health-related quality of life in survivors of brain tumors treated in childhood. Pediatr Blood Cancer 2006;46:357-62.

44. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone 2008;43:1115-21.

45. Halton JM, Atkinson SA, Fraher L, Webber C, Gill GJ, Dawson S, et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 1996;11:1774-83.

46. van der Sluis IM, van den Heuvel-Eibrink MM, Hahnen K, Krens E, de Ruiter ME, Peeters MC, et al. Changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf) 2003;60:175-84.

47. Mattano L. The skeletal remains: porosis and necrosis of bone in the marrow transplantation setting. Pediatr Transplant 2003;7 Suppl 3:71-5.

48. Le Meignen M, Auquier P, Barlogis V, Sirvent N, Contet A, Simeoni MC, et al. Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 2011;118:1481-9.

49. Muller HL, Schneider P, Bueh K, Etavard-Gorris N, Gebhardt U, Kolb R, et al. Volumetric bone mineral density in patients with childhood craniopharyngioma. Exp Clin Endocrinol Diabetes 2003;111:168-73.

50. Gurney JG, Kadan-Lottick NS, Packer R, Neglia JP, Sklar CA, Punyko JA, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood Cancer Survivor Study. Cancer 2003;97:663-73.
in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study. Pediatrics 2005;116:e102-8.
51. Jarfelt M, Fors H, Lannering B, Bjarnason R. Bone mineral density and bone turnover in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol 2006;154:303-9.
52. Brennan BM, Rahim A, Adams JA, Eden OB, Shalet SM. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer 1999;79:1859-63.
53. Brennan BM, Mughal Z, Roberts SA, Ward K, Shalet SM, Eden TO, et al. Bone mineral density in childhood survivors of acute lymphoblastic leukaemia treated without cranial irradiation. J Clin Endocrinol Metab 2005;90:689-94.
54. van Beek RD, van den Heuvel-Eibrink MM, Hakvoort-Cammel FG, van den Box C, van der Pal HJ, Krenning EP, et al. Bone mineral density, growth, and thyroid function in long-term survivors of pediatric Hodgkin’s lymphoma treated with chemotherapy only. J Clin Endocrinol Metab 2009;94:1904-9.
55. Ruza E, Sierrasesumaga L, Azcona C, Patino-Garcia A. Bone mineral density and bone metabolism in children treated for bone sarcomas. Pediatr Res 2006;59:866-71.
56. Muller C, Winter CC, Rosenbaum D, Boos J, Gosheger G, Hardes J, et al. Early decrements in bone density after completion of neo-adjuvant chemotherapy in pediatric bone sarcoma patients. BMC Musculoskelet Disord 2010;11:287.
57. Othman F, Guo CY, Webber C, Atkinson SA, Barr RD. Osteopenia in survivors of Wilms tumor. Int J Oncol 2002;20:827-33.
58. Al-Tonbary YA, El-Ziny MA, Elsharkawy AA, El-Hawary AK, El-Ashry R, Fouda AE. Bone mineral density in newly diagnosed children with neuroblastoma. Pediatr Blood Cancer 2011;56:202-5.
59. Daniels MW, Wilson DM, Paguntalan HG, Hoffman AR, Bachrach LK. Bone mineral density in pediatric transplant recipients. Transplantation 2003;76:673-8.
60. Kashyap A, Kandeel F, Yamauchi D, Palmer JM, Niland JC, Molina A, et al. Effects of allogeneic bone marrow transplantation on recipient bone mineral density: a prospective study. Biol Blood Marrow Transplant 2000;6(3A):344-51.
61. Kaste SC, Shidler TJ, Tong X, Srivastava DK, Rochester R, Hudson MM, et al. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant 2004;33:435-41.
62. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP. Mechanisms of bone loss following allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res 1999;14:342-50.
63. Da Silva AN, Heras-Herzig A, Schiff D. Bone health in patients with brain tumors. Surg Neurol 2007;68:525-33.
64. Rhee SY, Hwang YC, Chung HY, Woo JT. Vitamin D and diabetes in Koreans: analyses based on the fourth Korea National Health and Nutrition Examination Survey (KNHANES), 2008-2009. Diabet Med 2012;29:1003-10.
65. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab 2012;97:1153-8.
66. Kaste SC, Rai SN, Fleming K, McCammon EA, Tylavsky FA, Danish RK, et al. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2006;46:77-87.
67. Goldbloom EB, Cummings EA, Yhap M. Osteoporosis at presentation of childhood ALL: management with pamidronate. Pediatr Hematol Oncol 2005;22:543-50.
68. Barr RD, Guo CY, Wiernikowski J, Webber C, Wright M, Atkinson S. Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with Pamidronate. Med Pediatr Oncol 2002;39:44-6.
69. Patterson BC, Wasilewski-Masker K, Ryerson AB, Mertens A, Meacham L. Endocrine health problems detected in 519 patients evaluated in a pediatric cancer survivor program. J Clin Endocrinol Metab 2012;97:810-8.